A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2016
The purpose of this study was to demonstrate similarity of NI-071 (proposed biosimilar to infliximab) to US REMICADE® (reference product) in terms of safety and efficacy in participants with rheumatoid arthritis (RA) not adequately responding to methotrexate (MTX).
Epistemonikos ID: 6a21a340864f51e3c156f54dee48097b7d73dc26
First added on: Mar 23, 2022